The stock of Novo Nordisk (NVO -1.79%) has been a hot buy over the past few years (up 270% in three years), largely due to the success of its diabetes and weight loss drugs.Even if you aren't familiar with the company, you're probably familiar with Ozempic, which has been synonymous with weight loss even though it's approved as a treatment for diabetes. Wegovy is the company's approved weight loss drug, and it has been growing at a scorching rate, with its sales rising by more than 400% last year. And while ...

Novo Nordisk (NVO) closed the most recent trading day at $132.89, moving +0.39% from the previous trading session. This move lagged the S&P 500's daily gain of 0.63%. Elsewhere, the Dow gained 0.2%, while the tech-heavy Nasdaq added 0.82%.Coming into today, shares of the drugmaker had gained 6.74% in the past month. In that same time, the Medical sector gained 0.91%, while the S&P 500 gained 1.76%.Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming ear ...

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.The ...

The "Magnificent Seven" are helping lift major U.S. indexes to record highs. This group of highly acclaimed stocks -- among the heaviest-weighted equities in the S&P 500 -- is comprised of Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. There are good reasons to invest in all seven of these corporations, and that's why they've performed so well in recent years.However, some companies outside this clique are just as impressive and deserve to be considered on par with the Magnificent Se ...

Some pharmaceutical products have become massively popular in the past few years. The class of vaccines and drugs that help prevent and treat COVID-19 is a good example. These allowed us to contain the pandemic, so their fame is well deserved. Another category of drugs has been making plenty of noise lately: anti-obesity medicines.Perhaps the most famous is Wegovy, marketed by Novo Nordisk (NVO -1.64%). The Denmark-based drugmaker is a leader in this niche. Though Wegovy still has a long and bright future a ...

In this articleNVONOVO.B-DKVictoria Klesty | ReutersIn the U.S., Wegovy is no longer just for weight loss.The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage of the weekly injection drug from Novo Nordisk and similar obesity treatments just yet.Some employers and other health plans are still reluctant to cover Wegovy due to its hefty $1,350 m ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...

Danish pharmaceutical company Novo Nordisk (NVO -1.37%) has taken the world by storm thanks to its popular diabetes and obesity medications Ozempic, Rybelsus, and Wegovy.2023 was a milestone year for Novo Nordisk, with Ozempic and Wegovy playing lead roles in the company's growth. Just last week, Novo Nordisk received some positive news from the Food and Drug Administration (FDA), and the shares soared to new highs.Let's break down what's going on at Novo Nordisk and assess why the company's best days may b ...

A big focus for healthcare companies recently has been on the weight-loss industry. It's no coincidence that two of the most valuable healthcare stocks in the world are big players in that field with a couple of promising weight-loss treatments.Companies are eager to get glucagon-like peptide 1 (GLP-1) drugs to market because they could help bolster their long-term growth prospects. And investors are paying attention, as possessing the next big weight-loss drug could be a sign of a stock that's due to skyro ...

Who is better, the United States of America or the European Union? On the one hand, European citizens are by and large privy to free access to healthcare, though the land of the free is considerably less stingy with its food portion sizes. The benefits of each can be argued until the cows come home, but what about stock market performance? Deutsche Bank analysts have dug deep into the data to provide some enlightening comparisons between Europe’s ‘Fabulous 5’ big-cap stocks and the US’s ‘Magnificent 7’. You ...